Clinical and angiographic outcomes after intracoronary bare-metal stenting

I-Chang Hsieh1, Ming-Jer Hsieh2, Shang-Hung Chang1

  • 1Second Department of Cardiology, Percutaneous Coronary Intervention Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Linkou, Taoyuan, Taiwan.

Plos One
|April 15, 2014
PubMed

Insights

Very long-term outcomes after bare-metal stenting (BMS) show sustained luminal diameter improvement. However, coronary atherosclerosis progression necessitates new lesion stenting over time.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Medicine

Background:

  • Limited data exists on very long-term outcomes following bare-metal stent (BMS) implantation.
  • This study addresses the need for comprehensive clinical and angiographic data in a large patient cohort.

Purpose of the Study:

  • To evaluate very long-term (8-17 years) clinical outcomes after BMS implantation.
  • To assess long-term (3-5 years) angiographic results in patients treated with BMS.

Main Methods:

  • Analysis of data from the Cardiovascular Atherosclerosis and Percutaneous TrAnsluminal INterventions (CAPTAIN) registry.
  • Inclusion of 2391 patients treated with 3190 BMSs between 1995 and 2004.
  • Long-term clinical follow-up (mean 149 months) and angiographic follow-up at 6 months and 3-5 years.

Main Results:

  • Mean follow-up of 149 months revealed 18.6% mortality (10.8% cardiac), 6.1% reinfarction, and 16.2% target lesion revascularization.
  • 14.5% required new lesion stenting, with 72% occurring after 3 years, indicating progressive atherosclerosis.
  • Angiography showed a 20% restenosis rate at 6 months, with sustained luminal diameter improvement from 6 months to 3-5 years (2.06 mm to 2.27 mm).

Conclusions:

  • BMS implantation in a large patient population demonstrates clinical and angiographic outcomes over a very long-term follow-up period.
  • Coronary atherosclerosis progression is evident, leading to the need for new stent implantations over time.
  • Late and sustained improvement in luminal diameter is confirmed between 6 months and 3-5 years post-stenting.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493